Core-Out Fistulectomy Combined With Laser Ablation of the Trans-Sphincteric Fistula Tract: A Pilot Study of Efficacy and Safety

Emre Özoran; Sündüs Zeynep Küçüksümer Ertek; Mert Mahsuni Sevinç

doi:10.12659/MSM.951819

03 March 2026 : Clinical Research

Core-Out Fistulectomy Combined With Laser Ablation of the Trans-Sphincteric Fistula Tract: A Pilot Study of Efficacy and Safety

Emre Özoran

^{ABCDEF 1*}, Sündüs Zeynep Küçüksümer Ertek

^{BCDEF 2}, Mert Mahsuni Sevinç

^{AEF 3}

DOI: 10.12659/MSM.951819

Med Sci Monit 2026; 32:e951819

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Patient demographics and clinical data.

Patient	Age (yearrs)	Sex	BMI	Smoking status	Comorbidities	Number of prior surgeries	If applicable previous surgeries		Fistula duration (weeks)		Suppuration
1	52	M	38	Current	DM, HT, RA	0	NA		2		Yes
2	42	F	25	Current	–	2	Abscess drainage, seton placement		40		Yes
3	60	M	24	Never	–	2	Abscess drainage		104		No
4	59	M	23	Current	–	1	Abscess drainage		60		Yes
5	48	M	23	Never	–	0	NA		10		Yes
6	41	F	32	Current	–	2	Abscess drainage		96		No
7	30	M	33	Never	–	0	NA		20		Yes
8	50	M	29	Never	HT	1	Abscess drainage		12		No
9	45	F	36	Never	–	2	Abscess drainage, seton placement		82		Yes
10	25	F	24	Never	–	1	Abscess drainage		40		No
11	37	M	27	Never	–	1	Abscess drainage		5		No
12	43	M	23	Never	–	0	NA		22		Yes
13	29	F	19	Current	–	0	NA		30		Yes
14	19	M	35	Current	–	1	Abscess drainage		16		No
15	33	F	27	Current	–	1	Abscess drainage		23		No
16	22	F	20	Current	–	1	Abscess drainage		5		No
17	50	M	29	Never	HT	0	NA		19		Yes
18	40	M	34	Current	–	1	Abscess drainage		33		No
19	37	M	31	Never	–	2	Abscess drainage, seton placement		52		Yes
20	45	M	28	Current	–	1	Abscess drainage		8		No

1	None	58	25	Chronic Inflammation and fistula tract	7.0	12	0	0	NA	13	1
2	Yes	36	19	Chronic Inflammation and fistula tract	6.0	12	0	0	NA	4	1
3	None	38	20	Chronic Inflammation and fistula tract	8.0	11	0	0	NA	8	1
4	Yes	37	23	Chronic Inflammation and fistula tract	5.0	11	0	0	NA	9	1
5	None	35	17	Chronic Inflammation and fistula tract	nan	11	2	1	5	20	1
6	None	44	24	Chronic Inflammation and fistula tract	7.0	11	0	0	NA	10	1
7	None	49	27	Chronic Inflammation and fistula tract	6.0	11	0	0	NA	9	1
8	None	43	20	Chronic Inflammation and fistula tract	8.0	11	0	0	NA	11	1
9	Yes	52	30	Chronic Inflammation and fistula tract	10.0	10	0	0	NA	15	1
10	None	40	25	Chronic Inflammation and fistula tract	9.0	10	0	0	NA	14	1
11	None	39	23	Chronic Inflammation and fistula tract	8.0	10	0	0	NA	7	1
12	None	37	27	Chronic Inflammation and fistula tract	3.0	10	0	0	NA	6	1
13	None	36	22	Chronic Inflammation and fistula tract	5.0	9	0	0	NA	5	1
14	None	45	30	Chronic Inflammation and fistula tract	5.0	9	0	0	NA	3	1
15	None	42	19	Chronic Inflammation and fistula tract	4.0	9	0	0	NA	8	1
16	None	38	18	Chronic Inflammation and fistula tract	7.0	9	0	0	NA	9	1
17	None	41	23	Chronic Inflammation and fistula tract	6.0	8	0	0	NA	8	1
18	None	53	25	Chronic Inflammation and fistula tract	8.0	8	0	0	NA	6	1
19	Yes	42	23	Chronic Inflammation and fistula tract	nan	8	2	1	3	15	1
20	None	37	20	Chronic Inflammation and fistula tract	4.0	8	0	0	NA	5	1
M – Male; F – Female; DM – diabetes mellitus; HT – hypertension; RA – rheumatoid arthritis; NA – not applicable; PFDSS – perianal fistula disease severity score.

Back to the Article

Core-Out Fistulectomy Combined With Laser Ablation of the Trans-Sphincteric Fistula Tract: A Pilot Study of Efficacy and Safety

Your Privacy